BCTX

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.

Wall Street analysts forecast BCTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCTX is 39.90 USD with a low forecast of 39.90 USD and a high forecast of 39.90 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Briacell Therapeutics Corp revenue for the last quarter amounts to -8.32M USD, increased 61.52 % YoY.

Briacell Therapeutics Corp. EPS for the last quarter amounts to -7704796.00 USD, increased 10.78 % YoY.

Briacell Therapeutics Corp (BCTX) has 22 emplpoyees as of January 09 2026.

Today BCTX has the market capitalization of 13.71M USD.